Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable October 31, 2025, to shareholders of record at the close of business on September ...

Financial Results for the Second Quarter and Six Months Ended June 30, 2025 Please note: All share amounts and per share amounts in this press release have been adjusted to reflect the 1-for-8 reverse ...

CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...

Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, filed a patent infringement lawsuit against Balt ...

About VIVO ™ Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, ...

WOBURN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results ZUSDURI™ (mitomycin) for intravesical solution now available as the first and only ...

The podcast draws on insights from recent industry data, regulatory updates, and the Company’s own developments, offering a fresh perspective on Izotropic’s mission and its flagship product, IzoView, ...

Part A: SAD: The first two cohorts have been dosed with no treatment related serious adverse events (“SAEs”) reported. The third and final cohort in the SAD part of the trial is ongoing. SAD data is ...

Annovis achieves comprehensive intellectual property (IP) protection now covering both the original semi-crystalline and new ...

(GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced ...

Nualtis (formerly IntelGenx Corp.), a leader in oral film drug delivery technologies, today announced a strategic partnership with OrthoNu LLC to develop and manufacture an innovative portfolio of ...